Back to Search Start Over

Precision Medicine for Blood Glutamate Grabbing in Ischemic Stroke.

Precision Medicine for Blood Glutamate Grabbing in Ischemic Stroke.

Authors :
Hervella, Pablo
Sampedro-Viana, Ana
Fernández-Rodicio, Sabela
Rodríguez-Yáñez, Manuel
López-Dequidt, Iria
Pumar, José M.
Mosqueira, Antonio J.
Bazarra-Barreiros, Marcos
Abengoza-Bello, María Teresa
Ortega-Espina, Sara
Ouro, Alberto
Pérez-Mato, María
Campos, Francisco
Sobrino, Tomás
Castillo, José
Alonso-Alonso, Maria Luz
Iglesias-Rey, Ramón
Source :
International Journal of Molecular Sciences; Jun2024, Vol. 25 Issue 12, p6554, 14p
Publication Year :
2024

Abstract

Glutamate grabbers, such as glutamate oxaloacetate transaminase (GOT), have been proposed to prevent excitotoxicity secondary to high glutamate levels in stroke patients. However, the efficacy of blood glutamate grabbing by GOT could be dependent on the extent and severity of the disruption of the blood–brain barrier (BBB). Our purpose was to analyze the relationship between GOT and glutamate concentration with the patient's functional status differentially according to BBB serum markers (soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and leukoaraiosis based on neuroimaging). This retrospective observational study includes 906 ischemic stroke patients. We studied the presence of leukoaraiosis and the serum levels of glutamate, GOT, and sTWEAK in blood samples. Functional outcome was assessed using the modified Rankin Scale (mRS) at 3 months. A significant negative correlation between GOT and glutamate levels at admission was shown in those patients with sTWEAK levels > 2900 pg/mL (Pearson's correlation coefficient: −0.249; p < 0.0001). This correlation was also observed in patients with and without leukoaraiosis (Pearson's correlation coefficients: −0.299; p < 0.001 vs. −0.116; p = 0.024). The logistic regression model confirmed the association of higher levels of GOT with lower odds of poor outcome at 3 months when sTWEAK levels were >2900 pg/mL (OR: 0.41; CI 95%: 0.28–0.68; p < 0.0001) or with leukoaraiosis (OR: 0.75; CI 95%: 0.69–0.82; p < 0.0001). GOT levels are associated with glutamate levels and functional outcomes at 3 months, but only in those patients with leukoaraiosis and elevated sTWEAK levels. Consequently, therapies targeting glutamate grabbing might be more effective in patients with BBB dysfunction. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
16616596
Volume :
25
Issue :
12
Database :
Complementary Index
Journal :
International Journal of Molecular Sciences
Publication Type :
Academic Journal
Accession number :
178185982
Full Text :
https://doi.org/10.3390/ijms25126554